Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer.
Kawachi H, Yamada T, Tamiya M, Negi Y, Goto Y, Nakao A, Shiotsu S, Tanimura K, Takeda T, Okada A, Harada T, Date K, Chihara Y, Hasegawa I, Tamiya N, Ishida M, Katayama Y, Morimoto K, Iwasaku M, Tokuda S, Kijima T, Takayama K. Kawachi H, et al. Among authors: negi y. JAMA Netw Open. 2023 Jul 3;6(7):e2322915. doi: 10.1001/jamanetworkopen.2023.22915. JAMA Netw Open. 2023. PMID: 37432682 Free PMC article.
Successful Treatment of Pulmonary Pleomorphic Carcinoma with Nivolumab: A Case Report.
Fujimoto E, Yokoi T, Mikami K, Kanemura S, Shibata E, Horio D, Koda Y, Negi Y, Akano Y, Tada A, Minami T, Kuribayashi K, Kijima T. Fujimoto E, et al. Among authors: negi y. Case Rep Oncol. 2018 May 31;11(2):336-340. doi: 10.1159/000489392. eCollection 2018 May-Aug. Case Rep Oncol. 2018. PMID: 29928213 Free PMC article.
EphA2 inhibition suppresses proliferation of small-cell lung cancer cells through inducing cell cycle arrest.
Ishigaki H, Minami T, Morimura O, Kitai H, Horio D, Koda Y, Fujimoto E, Negi Y, Nakajima Y, Niki M, Kanemura S, Shibata E, Mikami K, Takahashi R, Yokoi T, Kuribayashi K, Kijima T. Ishigaki H, et al. Among authors: negi y. Biochem Biophys Res Commun. 2019 Nov 19;519(4):846-853. doi: 10.1016/j.bbrc.2019.09.076. Epub 2019 Sep 24. Biochem Biophys Res Commun. 2019. PMID: 31558317
Tumor-associated macrophage-derived inflammatory cytokine enhances malignant potential of malignant pleural mesothelioma.
Horio D, Minami T, Kitai H, Ishigaki H, Higashiguchi Y, Kondo N, Hirota S, Kitajima K, Nakajima Y, Koda Y, Fujimoto E, Negi Y, Niki M, Kanemura S, Shibata E, Mikami K, Takahashi R, Yokoi T, Kuribayashi K, Kijima T. Horio D, et al. Among authors: negi y. Cancer Sci. 2020 Aug;111(8):2895-2906. doi: 10.1111/cas.14523. Epub 2020 Jul 6. Cancer Sci. 2020. PMID: 32530527 Free PMC article.
Combination therapy with anti-programmed cell death 1 antibody plus angiokinase inhibitor exerts synergistic antitumor effect against malignant mesothelioma via tumor microenvironment modulation.
Tada A, Minami T, Kitai H, Higashiguchi Y, Tokuda M, Higashiyama T, Negi Y, Horio D, Nakajima Y, Otsuki T, Mikami K, Takahashi R, Nakamura A, Kitajima K, Ohmuraya M, Kuribayashi K, Kijima T. Tada A, et al. Among authors: negi y. Lung Cancer. 2023 Jun;180:107219. doi: 10.1016/j.lungcan.2023.107219. Epub 2023 Apr 26. Lung Cancer. 2023. PMID: 37146474 Free article.
Chemoimmunotherapy Versus Pembrolizumab as a First-Line Treatment for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression: Focus on the Role of Performance Status.
Morimoto K, Yamada T, Kawachi H, Tamiya M, Negi Y, Goto Y, Nakao A, Shiotsu S, Tanimura K, Takeda T, Okada A, Harada T, Date K, Chihara Y, Hasegawa I, Tamiya N, Nishioka N, Katayama Y, Iwasaku M, Tokuda S, Kijima T, Takayama K. Morimoto K, et al. Among authors: negi y. Target Oncol. 2023 Nov;18(6):915-925. doi: 10.1007/s11523-023-01012-1. Epub 2023 Oct 30. Target Oncol. 2023. PMID: 37902896
56 results